New Users of Antipsychotic Medications Among Children Enrolled in TennCare
Open Access
- 1 August 2004
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 158 (8), 753-759
- https://doi.org/10.1001/archpedi.158.8.753
Abstract
Background The use of antipsychotic medications in children and adolescents for indications other than psychosis or Tourette syndrome is controversial. Newer atypical antipsychotics with profiles of adverse effects that differ from those of traditional antipsychotics may lead providers to prescribe antipsychotics more frequently than in the past for behavioral indications not strongly supported by clinical study. Objective To identify population-based new use of antipsychotics among patients aged 2 to 18 years. Design Retrospective cohort study, January 1, 1996, through December 31, 2001. Setting Tennessee's managed care program for Medicaid enrollees and the uninsured (TennCare). Main Outcome Measures New use of antipsychotic medications and indications for use by the child's diagnosis, adjusted for age, sex, race, county of residence, enrollment category, and income. Results The proportion of TennCare children who were new users of antipsychotics, adjusted for demographic characteristics, nearly doubled from 23/10 000 in 1996 to 45/10 000 in 2001 (adjusted incidence rate ratio, 1.98; 95% confidence interval, 1.82-2.16). In 1996, 6.8% of new users received an atypical antipsychotic; by 2001, this had increased to 95.9%. New use for attention-deficit/hyperactivity disorder and affective disorders increased 2.5-fold. New use of antipsychotics for schizophrenia, acute psychotic reaction, Tourette syndrome, and mental retardation or autism remained relatively constant. Secular trends of increasing use were most pronounced for those aged 6 to 12 years (93% increase) and 13 to 18 years (116% increase), although use among preschool children increased 61% during the study period. Conclusion The proportion of TennCare children who became new users of antipsychotics nearly doubled from 1996 to 2001, with a substantial increase in use of antipsychotics for attention-deficit/hyperactivity disorder, conduct disorder, and affective disorders.Keywords
This publication has 22 references indexed in Scilit:
- Concomitant Psychotropic Medication for YouthsAmerican Journal of Psychiatry, 2003
- A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United StatesJournal of Clinical Epidemiology, 2003
- Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQsJournal of the American Academy of Child & Adolescent Psychiatry, 2002
- Risperidone in Children with Autism and Serious Behavioral ProblemsNew England Journal of Medicine, 2002
- Weight Gain Associated With Olanzapine and Risperidone in Adolescent Patients: A Comparative Prospective StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2002
- Open Trial of Risperidone in 24 Young Children With Pervasive Developmental DisordersJournal of the American Academy of Child & Adolescent Psychiatry, 2001
- Risperidone in the Treatment of Behavioral Disturbances in Children and Adolescents with Borderline Intellectual Functioning: A Double-Blind, Placebo-Controlled Pilot TrialJournal of Child and Adolescent Psychopharmacology, 2001
- Trends in the Prescribing of Psychotropic Medications to PreschoolersJama-Journal Of The American Medical Association, 2000
- Assessment and Management of Antipsychotic-Induced Adverse EventsThe Canadian Journal of Psychiatry, 1998
- A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental DisordersArchives of General Psychiatry, 1998